This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
Nanoparticle albumin-bound paclitaxel for breast cancer. Lansdale: HAYES, Inc.. Directory Publication. 2013
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) (Abraxane; Abraxis BioScience LLC, a wholly owned subsidiary of Celgene Corp.) is a chemotherapeutic drug that is administered alone or in combination with other agents for the purpose of delaying disease progression and prolonging survival in patients who have metastatic breast cancer. Nab-paclitaxel differs from standard paclitaxel in that it is a colloidal suspension of 130-nanometer albumin-bound nanoparticles of paclitaxel and is, therefore, free of solvents. The goals of this new nanotechnology-based formulation are to reduce toxicity and improve the bioavailability of paclitaxel.
Subject indexing assigned by CRD
Albumins; Antineoplastic Agents; Breast Neoplasmss; Paclitaxel
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: firstname.lastname@example.org
Date abstract record published